PR Newswire
SOUTH PLAINFIELD, N.J., March 16, 2017
SOUTH PLAINFIELD, N.J., March 16, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2016.
"For nearly 20 years, PTC has been committed to delivering new treatment options to patients living with Duchenne muscular dystrophy globally," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Our strong commercial performance in 2016 coupled with the advancements in our clinical programs brings us closer to that goal. I am proud of what we accomplished in 2016, and we will continue to work diligently to bring Translarna to patients globally, as well as develop treatments for additional rare, genetic disorders."
Fourth Quarter and Full Year 2016 Financial Highlights:
2017 Guidance:
Key 2016 Fourth Quarter and other Corporate Highlights:
Non-GAAP Financial Measures
In this press release, PTC's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, non-GAAP financial results exclude stock-based compensation expense and one-time restructuring expenses relating to the reorganization of operations intended to improve efficiency and better align costs and employment structure with the Company's strategic plans. These results are provided as a complement to results reported in GAAP, because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the operating performance at PTC and the company's future outlook.
PTC Therapeutics, Inc Consolidated Statements of Operations (In thousands, except per share data) | ||||||||||||||||
| ||||||||||||||||
| | Three Months Ended | | Twelve Months Ended | | |||||||||||
| | 2016 | | 2015 | | 2016 | | 2015 | | |||||||
| | | | | | | | | | |||||||
Revenues: | | | | | | | | | | |||||||
Net product revenue | | $ | 25,119 | | $ | 12,694 | | $ | 81,447 | | $ | 33,696 | | |||
Collaboration and grant revenue | | 72 | | 40 | | 1,258 | | 3,070 | | |||||||
Total revenues | | 25,191 | | 12,734 | | 82,705 | | 36,766 | | |||||||
Operating expenses: | | | | | | | | | | |||||||
Research and development (1) | | 26,011 | | 35,048 | | 117,633 | | 121,816 | | |||||||
Selling, general and administrative (2) | | 24,172 | | 25,887 | | 97,130 | | 82,080 | | |||||||
Total operating expenses | | 50,183 | | 60,935 | | 214,763 | | 203,896 | | |||||||
Loss from operations | | (24,992) | | (48,201) | | (132,058) | | (167,130) | | |||||||
Interest expense, net | | (2,127) | | (2,537) | | (8,276) | | (2,367) | | |||||||
Other income (expense), net | | 686 | | 42 | | (1,207) | | (465) | | |||||||
Loss before income tax expense | | (26,433) | | (50,696) | | (141,541) | | (169,962) | | |||||||
Income tax expense | | (363) | | (252) | | (569) | | (485) | | |||||||
Net loss attributable to common stockholders | | $ | (26,796) | | $ | (50,948) | | $ | (142,110) | | $ | (170,447) | | |||
| | | | | | | | | | |||||||
Weighted-average shares outstanding: | | | | | | | | | | |||||||
Basic and diluted (in shares) | | | 34,168,249 | | | 33,915,316 | | | 34,044,584 | | | 33,626,248 | | |||
Net loss per share—basic and diluted (in dollars per share) | | $ | (0.78) | | $ | (1.50) Werbung Mehr Nachrichten zur PTC Therapeutics Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |